- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Peter Maccallum Cancer Centre
Headquarters: East Melbourne, Australia
Website: http://www.petermac.org
Year Founded: 1949
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 15, 2024
Emerging Company Profile
BridGene: a pairwise approach to chemoproteomics for hard targets
The California company’s IMTAC screening platform for hard-to-drug targets has found partners in Takeda and Galapagos
BioCentury | Apr 11, 2023
Discovery & Translation
Inhalable nanoparticles for lung mRNA delivery and gene editing; nanobody secretion by E. coli in the gut and more
BioCentury’s roundup of translational news
BioCentury | Aug 27, 2021
Distillery Therapeutics
Stimulating mucosal-associated invariant T cells for melanoma, breast cancer
BioCentury | Jun 29, 2021
Deals
June 28 Quick Takes: STARs aligning for BeiGene trifecta; plus venture money for Neurona, Vita, Lyndra, Currus and Eikonoklastes
Monday’s authorization to list on the Shanghai Stock Exchange’s STAR market sets BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) up to add its third listing, pending approval by China Securities
BioCentury | May 30, 2020
Translation in Brief
Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more
BioCentury’s roundup of preclinical news
BioCentury | Aug 29, 2019
Distillery Therapeutics
Boosting cancer sensitivity to CDK4, CDK6 inhibitors by inhibiting the PRMT5-MDM4 axis
BioCentury | Mar 2, 2018
Clinical News
Senhwa reports Phase I data for CX-5461 in hematologic malignancies
BioCentury | Oct 19, 2017
Clinical News
Theragnostics reports Phase I data for prostate cancer imaging agent
Items per page:
1 - 10 of 39